Generation Bio (NASDAQ:GBIO – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research report issued to clients and investors on Wednesday, RTT News reports. They presently have a $11.00 target price on the stock.
A number of other equities research analysts have also issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Generation Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Wednesday, August 16th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 target price on shares of Generation Bio in a report on Thursday, August 3rd. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.05.
View Our Latest Research Report on GBIO
Generation Bio Stock Performance
Generation Bio (NASDAQ:GBIO – Get Free Report) last released its earnings results on Wednesday, August 2nd. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $0.88 million for the quarter, compared to analyst estimates of $7.50 million. Research analysts forecast that Generation Bio will post -2.05 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Generation Bio
Hedge funds and other institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. acquired a new stake in shares of Generation Bio in the 2nd quarter valued at $26,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Generation Bio in the 1st quarter valued at $47,000. American Century Companies Inc. purchased a new position in shares of Generation Bio in the 1st quarter valued at $49,000. SG Americas Securities LLC purchased a new position in shares of Generation Bio in the 3rd quarter valued at $51,000. Finally, Barclays PLC grew its position in shares of Generation Bio by 533.0% in the 4th quarter. Barclays PLC now owns 12,913 shares of the company’s stock valued at $51,000 after buying an additional 10,873 shares during the last quarter. 95.81% of the stock is currently owned by institutional investors and hedge funds.
Generation Bio Company Profile
Generation Bio Co, a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
Featured Stories
- Five stocks we like better than Generation Bio
- Compound Interest and Why It Matters When Investing
- 3 High Dividend Stocks To Beat Treasury Yields
- How to Evaluate a Stock Before BuyingÂ
- United Airlines Shares Fall Despite Solid Quarter
- How to Start Investing in Real Estate
- Housing Starts Up, Homebuilders Down as Mortgage Rates Soar
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
